中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
8期
845-848
,共4页
瑞舒伐他汀%代谢综合征%胰岛素抵抗%血管生成素-2%超敏C反应蛋白
瑞舒伐他汀%代謝綜閤徵%胰島素牴抗%血管生成素-2%超敏C反應蛋白
서서벌타정%대사종합정%이도소저항%혈관생성소-2%초민C반응단백
Rosuvastatin%Metabolic syndrome%Insulin resistance%Angiopoietin-2%Highsensitivity C-reactive protein
目的 观察瑞舒伐他汀对代谢综合征(MS)患者血清血管生成素-2(Ang-2)和超敏C反应蛋白(hs-CRP)的影响及其安全性.方法 将80例MS患者分为治疗组40例和对照组40例.两组均给予降压治疗,同时治疗组加用瑞舒伐他汀10 mg/d口服,疗程8周.对照组不用任何调脂药.治疗前和治疗后8周分别检测血清Ang-2、hs-CRP浓度及肝、肾功能,比较两组治疗前、后各相关指标的差异.结果(1)治疗组治疗8周后Ang-2和hs-CRP浓度较治疗前显著降低[(1.81 ±0.47) μg/L降至(0.30±0.01) μg/L,(6.32±1.28) mg/L降至(2.02±0.26) mg/L;t=9.02、t=5.75,P均＜0.01];而对照组上述指标在治疗前后比较差异均无统计学意义[(1.80±0.45)μg/L与(1.79±0.48) μg/L,(6.28±1.34)mg/L与(6.20±1.42) mg/L;t =0.19、t =0.23,P均＞0.05].(2)治疗8周后治疗组的Ang-2和hs-CRP 浓度与对照组相比明显降低[(0.30 ±0.01) μg/L与(1.79±0.48) μg/L,(2.02±0.26) mg/L与(6.20±1.42) mg/L;t =2.34、=2.58,P均＜0.05].(3)治疗组不良反应少,安全性好.结论 瑞舒伐他汀可降低MS患者血清Ang-2和hs-CRP浓度,改善胰岛素抵抗,其安全性良好.
目的 觀察瑞舒伐他汀對代謝綜閤徵(MS)患者血清血管生成素-2(Ang-2)和超敏C反應蛋白(hs-CRP)的影響及其安全性.方法 將80例MS患者分為治療組40例和對照組40例.兩組均給予降壓治療,同時治療組加用瑞舒伐他汀10 mg/d口服,療程8週.對照組不用任何調脂藥.治療前和治療後8週分彆檢測血清Ang-2、hs-CRP濃度及肝、腎功能,比較兩組治療前、後各相關指標的差異.結果(1)治療組治療8週後Ang-2和hs-CRP濃度較治療前顯著降低[(1.81 ±0.47) μg/L降至(0.30±0.01) μg/L,(6.32±1.28) mg/L降至(2.02±0.26) mg/L;t=9.02、t=5.75,P均＜0.01];而對照組上述指標在治療前後比較差異均無統計學意義[(1.80±0.45)μg/L與(1.79±0.48) μg/L,(6.28±1.34)mg/L與(6.20±1.42) mg/L;t =0.19、t =0.23,P均＞0.05].(2)治療8週後治療組的Ang-2和hs-CRP 濃度與對照組相比明顯降低[(0.30 ±0.01) μg/L與(1.79±0.48) μg/L,(2.02±0.26) mg/L與(6.20±1.42) mg/L;t =2.34、=2.58,P均＜0.05].(3)治療組不良反應少,安全性好.結論 瑞舒伐他汀可降低MS患者血清Ang-2和hs-CRP濃度,改善胰島素牴抗,其安全性良好.
목적 관찰서서벌타정대대사종합정(MS)환자혈청혈관생성소-2(Ang-2)화초민C반응단백(hs-CRP)적영향급기안전성.방법 장80례MS환자분위치료조40례화대조조40례.량조균급여강압치료,동시치료조가용서서벌타정10 mg/d구복,료정8주.대조조불용임하조지약.치료전화치료후8주분별검측혈청Ang-2、hs-CRP농도급간、신공능,비교량조치료전、후각상관지표적차이.결과(1)치료조치료8주후Ang-2화hs-CRP농도교치료전현저강저[(1.81 ±0.47) μg/L강지(0.30±0.01) μg/L,(6.32±1.28) mg/L강지(2.02±0.26) mg/L;t=9.02、t=5.75,P균＜0.01];이대조조상술지표재치료전후비교차이균무통계학의의[(1.80±0.45)μg/L여(1.79±0.48) μg/L,(6.28±1.34)mg/L여(6.20±1.42) mg/L;t =0.19、t =0.23,P균＞0.05].(2)치료8주후치료조적Ang-2화hs-CRP 농도여대조조상비명현강저[(0.30 ±0.01) μg/L여(1.79±0.48) μg/L,(2.02±0.26) mg/L여(6.20±1.42) mg/L;t =2.34、=2.58,P균＜0.05].(3)치료조불량반응소,안전성호.결론 서서벌타정가강저MS환자혈청Ang-2화hs-CRP농도,개선이도소저항,기안전성량호.
Objective To observe the impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome(MS) to collect data on safety of rosuvastatin in treating MS.Methods Eighty MS patients were enrolled and divided into the treatment group(n =40) and the control group(n =40).The treatment group received both antihypertensive therapy and rosuvastatin with a dose of 10 mg/d.While the control group were only given antihypertensive therapy and but not any lipid-lowering drugs.The levels of plasma Ang-2 and hs-CRP and liver and kidney functions were measured and compared before and after 8-week treatment.Results (1) The levels of plasma Ang-2 and hs-CRP were significantly lower after 8 weeks than before treatment in the treatment groups[Ang-2:(0.30±0.01) μg/L vs.(1.81±0.47) μg/L,t =9.02,P ＜0.01 ;hs-CRP:(2.02±0.26) mg/L vs.(6.32±1.28) mg/L,t =5.75,P ＜ 0.01].Whereas statistical difference was not found in the control group[Ang-2:(1.80±0.45) μg/L vs.(1.79±0.48) μg/L,t =0.19,P > 0.05 ; hs-CRP:(6.28±1.34) mg/L vs.(6.20±1.42) mg/L,t =0.23,P ＞ 0.05].(2) After 8 weeks'treatment,the levels of plasma Ang-2 and hs-CRP were significantly lower in the treatment group than in the control group[Ang-2:(0.30±0.01) μg/L vs.(1.79±0.48) μμg/L,t =2.34,P ＜ 0.05 ;(2.02±0.26) mg/Lvs.(6.20±1.42) mg/L,t =2.58,P ＜ 0.05].(3) The adverse reaction in the treatment group was fewer than the control group and the security of rosuvastatin treatment on MS was fine.Conclusion Rosuvastatin can reduce plasma Ang-2 and hs-CRP levels and improve insulin resistance in patients with MS.Its security is fine.
